Insights into the Human CD59 Complement Binding Interface Toward Engineering New Therapeutics

• Published in: The Journal of biological chemistry Vol. 280; no. 40; pp. 34073 - 34079
• Main Authors: Huang, Yuxiang, Smith, Colin A., Song, Hongbin, Morgan, B. Paul, Abagyan, Ruben, Tomlinson, Stephen
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 07-10-2005; American Society for Biochemistry and Molecular Biology
• Subjects: Alanine; Animals; CD59 Antigens - genetics; CD59 Antigens - physiology; CHO Cells; Complement Membrane Attack Complex - physiology; Cricetinae; Cricetulus; Magnetic Resonance Spectroscopy; Models, Chemical; Mutagenesis, Site-Directed; Protein Conformation; Protein Engineering
• ISSN: 0021-9258; 1083-351X
• DOI: 10.1074/jbc.M504922200

CD59 is a 77-amino acid membrane glycoprotein that plays an important role in regulating the terminal pathway of complement by inhibiting formation of the cytolytic membrane attack complex (MAC or C5b-9). The MAC is formed by the self assembly of C5b, C6, C7, C8, and multiple C9 molecules, with CD59 functioning by binding C5b-8 and C5b-9 in the assembling complex. We performed a scanning alanine mutagenesis screen of residues 16–57, a region previously identified to contain the C8/C9 binding interface. We have also created an improved NMR model from previously published data for structural understanding of CD59. Based on the scanning mutagenesis data, refined models, and additional site-specific mutations, we identified a binding interface that is much broader than previously thought. In addition to identifying substitutions that decreased CD59 activity, a surprising number of substitutions significantly enhanced CD59 activity. Because CD59 has significant therapeutic potential for the treatment of various inflammatory conditions, we investigated further the ability to enhance CD59 activity by additional mutagenesis studies. Based on the enhanced activity of membrane-bound mutant CD59 molecules, clinically relevant soluble mutant CD59-based proteins were prepared and shown to have up to a 3-fold increase in complement inhibitory activity.